MAP Program
Discover, Reveal and Target
Proprietary Technology Platform
Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology, or MAP, platform, is built on three central pillars:
Efficient Screening & Validation of Oncogenic Mutations
MAP Platform:

Black Diamond’s Tumor Agnostic Precision Medicine Strategy
Expanding the Opportunity for Precision Medicine in Oncology:

Expanding the Opportunity for Precision Medicine in Oncology
